Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia

Published:2022-11-17 Issue:2 Volume:42 Page:124-137
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Ma Dan,Liu Ping,Hu Chujiao,Zhou Zhen,Wang Ping,Wang Yan,Zhang Yaming,Ran Yunsheng,Li Pinghao,Zhao Jiangyuan,Wang Jishi^ORCID,Zhang Chengliang,Tang Lei

Funder

National Natural Science Foundation of China

Guizhou Science and Technology Department

Department of Health of Guizhou Province

Research Center for Innovative & Generic Chemical Drug, Guizhou High-level Innovative Talents Supporting Program

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

https://www.nature.com/articles/s41388-022-02536-y.pdf

Reference40 articles.

1. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.

2. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.

3. Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past. Cells. 2021;10:117.

4. Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37:530–42.

5. Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, et al. Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition. J Natl Cancer Inst. 2018;110:467–78.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zinc as a potential regulator of the BCR-ABL oncogene in chronic myelocytic leukemia cells;Journal of Trace Elements in Medicine and Biology;2024-05

2. Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma;Frontiers in Pharmacology;2023-11-15

3. Dysregulated Signalling Pathways Driving Anticancer Drug Resistance;International Journal of Molecular Sciences;2023-07-30

4. Design, Synthesis, and Cytotoxic Activities of Indole and Indazole‐Based Stilbenes;Chemistry & Biodiversity;2023-04-18

5. An overview of the molecular and clinical significance of the angiopoietin system in leukemia;Journal of Receptors and Signal Transduction;2023-03-04